Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the Global Biodefense Market was valued at US$ 16.3 billion in 2021 and is expected to register a revenue CAGR of 8% to reach US$ 32.58 billion by 2030.

Market Fundamentals

Biodefense is a series of medical or military strategies adopted in response to restoring a country's biosecurity against biological toxins and infectious agents that can be used to kill or infect humans, animals, or the environment, as well as to initiate biological warfare. Living organisms like bacteria, viruses, fungi, and poisons can be utilized as bioterrorism agents. These substances have the potential to be intentionally utilized to infect and kill people to disrupt social and economic order.

[87349534]

Market Dynamics

Governments globally are taking the initiative to improve the defense system to protect the economy from any damages caused by bioterrorism attacks, the main driving factor of the global biodefense market revenue. Moreover, the rise in investment in R&D activities by the biopharmaceutical and pharmaceutical industries is also boosting the global market revenue growth. There is a rise in the incorporation of advanced technologies to innovate biothreat detection systems that help in the effective detection of bacteria and viruses. The availability of highly developed biothreat detection technologies will ensure the protection and security of the population, thus playing a pivotal role in the revenue growth of the global market. Similarly, the continuous launch of novel products and the developing biotechnology industry is also expected to fuel the global market revenue growth. However, the cost of R&D activities for vaccine development against bioterrorism attacks is high and is a major restricting factor of the global biodefense market revenue. Moreover, the lack of funds and adequate facilities for R&D, distribution, and healthcare in developing countries hinders global market revenue growth.

Market Ecosystem

The global biodefense market has been analyzed from three perspectives: product, end user, and region. 

Biodefense Market by Product

[3493824]

Based on product, the global biodefense market has been segmented into detection products and vaccines. 

The vaccine segment dominates the global biodefense market, with the largest market revenue share. The vaccines segment is further sub-segmented into anthrax, smallpox, botulism, radiation vaccine, and others. Anthrax is one of the most popular bioweapons since it can be placed in food, drink, and powder. They are frequently found in nature and have a long environmental shelf life in soil, plants, and water, thus, increasing demand for anthrax vaccines. Moreover, governments globally are taking the initiative and investing in drug developments for anthrax boosting the segment’s revenue growth.

The detection products segment accounts for the second-largest revenue share of the global biodefence market. Segmented detection products are further sub-segmented into samplers, detectors/triggering devices, identifiers, assays, and others. The increased assays in developing new vaccines and drugs boost the segment’s revenue growth. The demand for assays is growing as it reduces time and the overall cost of vaccine development. Moreover, the corporation of technologies such as high throughput screening, ELISA microarray assay, next gene sequencing, and Lab-on-Chip Devices are highly sensitive and quantitative-based assays that can detect multiple antigen-specific antibodies at deficient levels, thus propelling the segment’s revenue growth. 

Biodefense Market by End-User

Based on end-user, the global biodefense market is segmented into hospitals, military, ambulatory care centers, research organizations, and others. 

The hospital segment dominates the global biodefense market with the largest revenue share. The large revenue growth of the hospital segment can be attributed to patient data from hospitals of a previous infectious outbreak. Moreover, hospitals have well-developed infrastructure and experienced professionals, boosting the segment’s revenue growth. Furthermore, hospitals and medical institutes collaborate to develop innovative technologies unexpected events.

Biodefense Market by Region

Based on region, the global biodefense market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominates the global biodefense market with the largest revenue share, followed by Europe and Asia Pacific as the fastest-growing regions. The dominating revenue share of North America can be attributed to the high investment by the government in biodefense. Moreover, the well-developed biodefense market, with the presence of the top market players in the region, is fueling regional revenue growth. There are a large number of research institutes in the region that are developing innovative technologies for biodefense, propelling regional revenue growth. 

Competitive Landscape

The prominent players operating in the global biodefense market are:

• Alexeter Technologies LLC
• Altimmune Inc.
• Emergent Biosolutions Inc.
• Dynavax Technologies Corporation
• Bavarian Nordic
• ANP Technologies
• SIGA Technologies
• Biosearch Technologies
• Bruker Detection
• Elusys Therapeutics Inc.
• Ichor Medical Systems Inc.
• BioFire Defense (bioMérieux SA)
• PositiveID Corporation
• Dynport Vaccine Company

Strategic Developments

• In October 2022, Venatorx Pharmaceuticals received a project from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services (HHS), for the development of cefepime-taniborbactam for the treatment of melioidosis.
• In February 2022, Appili Therapeutics Inc. received over US$10 million in funding from the U.S. Department of Defense (DOD) for biodefense vaccine candidate ATI-1701, a potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis.

Frequently Asked Questions About This Report